Ask AI
ProCE Banner Activity

Llamamiento a la acción para mejorar resultados en el manejo de la leucemia linfocítica crónica (LLC) recidivante/refractaria al tratamiento oncológico  

PDF

En este comentario, tres expertos especialistas en el tratamiento de LLC reconocidos internacionalmente proveen respuestas a algunas de las preguntas clínicas más urgentes y frecuentes que surgen en la era moderna de los tratamientos dirigidos. Sus conocimientos prácticos ofrecen guía sobre la secuenciación, la evaluación de la resistencia, el uso de biomarcadores, y las dificultades de la gestión en el mundo real de la leucemia linfocítica crónica (LLC) recidivante/refractaria.

Released: February 12, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with Lymphoma Coalition.

ProCE Banner

Supporters

Supported by educational grants from Lilly and Merck Sharp & Dohme LLC.

Lilly

Merck Sharp & Dohme, LLC

Partners

Lymphoma Coalition

ProCE Banner

Target Audience

This activity has been designed to meet the educational needs of global hematologists, oncologists, nurse practitioners, physician associates, oncology nurses, pharmacists, and other healthcare professionals caring for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan individualized treatment sequences to optimize clinical outcomes for patients with relapsed/refractory CLL/SLL, considering available evidence, local expert recommendations, regional guidelines, and disease/patient factors

  • Appraise emerging clinical evidence for novel BTK-targeted therapies and the clinical implications for management of relapsed/refractory CLL/SLL

  • Assess resistance mutations in patients with relapsed/refractory CLL/SLL who progressed on or following covalent BTK inhibitor therapy

  • Implement multidisciplinary team processes to mitigate the risk of treatment- and disease-related complications in patients with relapsed/refractory CLL/SLL

  • Apply shared decision-making strategies to support patient quality of life and engagement in care for relapsed/refractory CLL/SLL

Disclosure

Primary Author

Stéphane Lepretre, MD, has no relevant financial relationships to disclose.

Stephen Stilgenbauer, MD: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Galapagos, Gilead, GSK, Hoffmann-La Roche, Johnson & Johnson; researcher: AbbVie, Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Galapagos, Gilead, GSK, Hoffmann-La Roche, Johnson & Johnson.

Alessandra Tedeschi, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeOne, Johnson & Johnson, Lilly.